Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom

Next Previous
Trial Profile

A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine (Primary) ; NVX CoV 2373 (Primary) ; Matrix M
  • Indications COVID-19 respiratory infection
  • Focus Registrational; Therapeutic Use
  • Sponsors Novavax

    • Most Recent Events

    • 18 Oct 2023 According to a Novavax media release, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has granted full marketing authorization for its prototype COVID-19 vaccine Nuvaxovid for individuals aged 12 and older for active immunization to help prevent COVID-19.
    • 14 Mar 2023 Status changed from active, no longer recruiting to completed.
    • 10 Oct 2022 protocol was amended on 25 February 2021 to include a blinded crossover phase in which subsequent doses of study vaccine were administered from 29 March to 14 June 2021, so all participants could receive active vaccine during the study as per results published in the Clinical Infectious Diseases.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top